FINANCIAL EXPRESS



Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai 400 026.

Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Andheri (East), Mumbai 400 099.

Tel: 91 22 4018 9999 Fax: 91 22 4018 9986 Email: complianceofficer@glenmarkpharma.com Website: www.glenmarkpharma.com

CIN: L24299MH1977PLC019982

Statement of unaudited financial results for the quarter and half year ended 30 September, 2018 (s in Millions)

╟	Т	Standalone (Ind AS)					Consolidated (Ind AS) Consolidated (IFRS)							(< in Millions)						
Ш			Quarter	Quarter	Quarter	Half Year	Half Year	Year	Quarter	Quarter	Quarter	Half Year	Half Year	Year	Quarter	Quarter	Quarter	Half Year	Half Year	Year
Ш		Particulars	Ended	Ended	Ended	Ended	Ended	Ended	Ended	Ended	Ended	Ended	Ended	Ended	Ended	Ended	Ended	Ended	Ended	Ended
		(Refer notes below)	30-09-2018 (Unudited)	30-06-2018 (Unaudited)	30-09-2017 (Unaudited)	30-09-2018 (Unaudited)	30-09-2017 (Unaudited)	31-03-2018 (Audited)	30-09-2018 (Unaudited)	30-06-2018 (Unaudited)	30-09-2017 (Unaudited)	30-09-2018 (Unaudited)	30-09-2017 (Unaudited)	31-03-2018 (Audited)	30-09-2018 (Unaudited)	30-06-2018 (Unaudited)	30-09-2017 (Unaudited)	30-09-2018 (Unaudited)	30-09-2017 (Unaudited)	31-03-2018 (Audited)
	_	Revenue from operations	(Ondanou)	(onduction)	(Oridaditou)	(Ondudantou)	(Giladaliou)	(riaditod)	(Giladaitea)	(Gildaditod)	(Gridadited)	(Gilladallou)	(Gildaditou)	(rtauttou)	(Giladaitea)	(Gridaditod)	(Gildaditou)	(Gildaditod)	(Onduditod)	(riaditou)
Ш	.	(a) Net sales	16,398.12	13,606.68	13,911.26	30,004.80	26,995.29	52,434.15	25,398.57	21,293.66	22,234.40	46,692.23	45,528.34	89,722.32	25,398.57	21,293.66	22,234.40	46,692.23	45,528.34	89,722.32
Ш		(b) Other operating income	399.03	451.69	360.76	850.72	684.09	3,007.93	414.75	362.51	331.50	777.26	667.58	1,308.38	414.75	362.51	331.50	777.26	667.58	1,308.38
Ш.		Total Revenue from operations	16,797.15	14,058.37	14,272.02	30,855.52	27,679.38	55,442.08	25,813.32	21,656.17	22,565.90	47,469.49	46,195.92	91,030.70	25,813.32	21,656.17	22,565.90	47,469.49	46,195.92	91,030.70
Ш.	<u>".</u>	Other income	2,263.02	1,655.64	563.04	3,918.66	988.66	1,799.92	1,398.79	1,382.16	297.26	2,780.95	450.13	914.00	1,398.62	1,382.16	297.26	2,780.78	450.13	914.00
H¦	"	Total income (I + II) Expenses	19,060.17	15,714.01	14,835.06	34,774.18	28,668.04	57,242.00	27,212.11	23,038.33	22,863.16	50,250.44	46,646.05	91,944.70	27,211.94	23,038.33	22,863.16	50,250.27	46,646.05	91,944.70
П.	١ '	a) Cost of materials consumed	3,859.17	4,084.98	3,776.36	7,944.15	7,564.84	16,480.25	6,032.60	4,951.83	5,443.85	10,984.43	10,300.52	21,501.10	6,032.60	4,951.83	5,443.85	10,984.43	10,300.52	21,501.10
Ш		b) Purchase of stock-in-trade	881.14	746.72	664.07	1,627.86	1,357.13	2,881.77	2,678.13	2,452.52	1,342.18	5,130.65	3,951.34	7,547.45	2,678.13	2,452.52	1,342.18	5,130.65	3,951.34	7,547.45
Ш		c) Changes in inventories of finished goods,						·												
Ш		work-in-progress and stock-in-trade	1,134.01	440.08	877.04	1,574.09	1,357.55	1,397.14	97.36	183.62	726.44	280.98	475.07	1,337.12	97.36	183.62	726.44	280.98	475.07	1,337.12
Ш		d) Employee benefits expense	3,123.98	2,012.70	2,867.65	5,136.68	4,687.79	8,956.71	6,058.95	4,525.09	5,572.30	10,584.04	9,416.26	18,718.41	6,058.95	4,525.09	5,572.30	10,584.04	9,416.26	18,718.41
Ш		e) Finance costs f) Depreciation and Amortisation expense	608.53 269.23	551.71 273.05	474.41 235.12	1,160.24 542.28	931.78 481.91	1,908.98 959.27	851.27 824.50	790.12 793.84	698.44 752.28	1,641.39 1,618.34	1,407.05 1,529.60	2,855.67 3,018.76	851.27 933.67	790.12 944.78	698.44 874.05	1,641.39 1,878.45	1,407.05 1,751.26	2,855.67 3,540.67
Ш		g) Other expenses	3,880.74	3,598.25	2,882.90	7,478.99	6,610.89	14,716.17	6,545.22	6,074.28	5,597.17	12,619.50	12,394.28	25,772.89	6,545.22	6,074.28	5,597.55	12,619.50	12,395.37	25,776.33
Ш		Total expenses (IV)	13,756.80	11,707.49	11,777.55	25,464.29	22,991.89	47,300.29	23,088.03	19,771.30	20,132.66	42,859.33	39,474.12	80,751.40	23,197.20	19,922.24	20,254.81	43,119.44	39,696.87	81,276.75
II۱	V	Profit/(loss) before exceptional items and tax(III - IV)	5,303.37	4,006.52	3,057.51	9,309.89	5,676.15	9,941.71	4,124.08	3,267.03	2,730.50	7,391.11	7,171.93	11,193.30	4,014.74	3,116.09	2,608.35	7,130.83	6,949.18	10,667.95
H.\	/	Exceptional items	(3,451.85)	-	-	(3,451.85)		-	(1,671.82)	-	-	(1,671.82)		-	(1,671.82)	-	-	(1,671.82)	-	
,		Profit/(loss) before tax (V - VI)	8,755.22	4,006.52	3,057.51	12,761.74	5,676.15	9,941.71	5,795.90	3,267.03	2,730.50	9,062.93	7,171.93	11,193.30	5,686.56	3,116.09	2,608.35	8,802.65	6,949.18	10,667.95
'	'''	Tax expense : Current tax	1.915.64	761.55	581.67	2.677.19	1.086.25	2,018.21	2,145.00	1,116.28	976.19	3,261.28	1,766.32	3,256.90	2,145.00	1,116.28	976.19	3,261.28	1,766.32	3,244.11
Ш		Deferred tax	(186.17)	(105.20)	(329.21)	(291.37)	(540.25)	(735.11)	(489.10)	(179.15)	(386.89)	(668.25)	(69.40)	(102.30)	(507.71)	(227.98)	(410.95)	(735.69)	(115.02)	(318.99)
1		Profit/(loss) for the period	(,	(**************************************	(,	(,	((* /	((**************************************	(,	(====,	(/	(**************************************	(,	((,	(* /	(,	(, , , , , , , , , , , , , , , , , , ,
Ш		from continuing operations (VII - VIII)	7,025.75	3,350.17	2,805.05	10,375.92	5,130.15	8,658.61	4,140.00	2,329.90	2,141.20	6,469.90	5,475.01	8,038.70	4,049.27	2,227.79	2,043.11	6,277.06	5,297.88	7,742.83
	X	Profit/(loss) for the period	000.00	0.47.07		4 000 00	4 000 00	004054												
$ \rangle$,	from continuing operations (V - VI) Tax expense of discontinuing operations:	683.02	947.07	716.74	1,630.09	1,296.62	2,246.54	-	-	-	-	-	-	-	-	-	-	-	-
Π'	`'	Current tax	222.51	308.53	219.68	531.04	397.41	688.56	_	_	_	_	_	_	_	_	_	_	_	_
Ш		Deferred tax	10.67	14.80	23.32	25.47	42.19	73.12	-	_	-	-	-	-	-	_	-	-	-	-
×	(II	Profit/(loss) for the period from																		
Ш.,		discontinuing operations (X - XI)	449.84	623.74	473.74	1,073.58	857.02	1,484.86	-	-	-	-	-	-	-	-	-	-	-	-
l I X	.'''	Profit/(loss) for the period for continuing and	7 475 50	3,973.91	3,278.79	11,449.50	5,987.17	10,143.47	4,140.00	2,329.90	2,141.20	6,469.90	5,475.01	8,038.70	4,049.27	2,227.79	2,043.11	6,277.06	5,297.88	7,742.83
$ _{x}$	ıv	discontinuing operations (IX + XII) Other comprehensive income	7,475.59	3,973.91	3,276.79	11,449.50	5,967.17	10,143.47	4,140.00	2,329.90	2,141.20	6,469.90	5,475.01	0,030.70	4,049.27	2,221.19	2,043.11	0,277.00	5,297.00	7,742.03
H^		A (i) Items that will not be reclassified to profit or loss	(48.45)	25.10	(26.09)	(23.35)	(34.69)	(10.20)	3.74	28.10	50.33	31.84	34.87	41.96	3.74	28.10	50.33	31.84	34.87	41.96
Ш		(ii) Income tax relating to items that will not be	, ,		, ,	, ,	, ,	, ,												
Ш		reclassified to profit or loss	16.93	(8.77)	9.02	8.16	12.00	3.53	10.15	(9.16)	(1.02)	0.99	2.96	(3.25)	10.15	(9.16)	(1.02)	0.99	2.96	(3.25)
Ш		B (i) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be	-	-	-	-	-	-	(600.23)	(2,725.02)	(14.41)	(3,325.25)	(368.92)	(778.78)	(557.92)	(2,753.50)	55.73	(3,311.42)	(294.46)	(696.17)
Ш		reclassified to profit or loss	_	_	_	_	_	_	127.67	_	_	127.67	_	_	127.67	_	_	127.67	_	_
lIх	v	Total comprehensive income	7,444.07	3,990.24	3,261.72	11,434.31	5,964.48	10,136.80	3,681.33	(376.18)	2,176.10	3,305.15	5,143.92	7,298.63	3,632.91	(506.77)	2,148.15	3,126.14	5,041.25	7,085.37
x	VI	Total comprehensive income attributable to:	,		,	,	,	ŕ	,	,	,	,	,	,	ŕ	, ,	,	,	,	
Ш		- Non-controlling interests		-	<u>.</u>	-		-	(0.04)	(0.04)	(0.32)	(0.08)	(0.19)	0.92	(0.04)	(0.04)	(0.32)	(0.08)	(0.19)	0.92
\prod_{v}	.,,,	- Owners of the Company Other equity	7,444.07	3,990.24	3,261.72	11,434.31	5,964.48	10,136.80 1,03,632.24	3,681.37	(376.14)	2,176.42	3,305.23	5,144.11	7,297.71	3,632.95	(506.73)	2,148.47	3,126.22	5,041.44	7,084.45
		Other equity Earning per share (EPS) (for continuing operations)	-	_	_	_	-	1,03,032.24	_	_	-	_	-	51,352.60	-	_	_	_	_	55,608.37
H^	``''	(of Re 1/- each) (not annualised)																		
Ш		Basic EPS (in Rupees)	24.90	11.87	9.94	36.78	18.18	30.69	14.67	8.26	7.59	22.93	19.40	28.49	14.35	7.90	7.24	22.25	18.78	27.44
Ш.,		Diluted EPS (in Rupees)	24.90	11.87	9.94	36.78	18.17	30.69	14.67	8.26	7.59	22.93	19.40	28.49	14.35	7.90	7.24	22.25	18.77	27.44
l lx	VIII	Earning per share (EPS) (for discontinuing operations)																		
Ш		(of Re 1/- each) (not annualised) Basic EPS (in Rupees)	1.59	2.21	1.68	3.80	3.04	5.26	_	_	_	_	_	_	_	_	_	_	_	
		Diluted EPS (in Rupees)	1.59	2.21	1.68	3.80	3.04	5.26] -	_	_	-	_	_	_]		-	_	-
X۱	VIII∨	Earning per share (EPS)					0.01	5.20												
		(for continuing and discontinuing operations)																		
Ш		(of Re 1/- each) (not annualised)	60.15				61.65	6= 6=				00.00	40.45		44.0-				10 ==	6
Ш		Basic EPS (in Rupees) Diluted EPS (in Rupees)	26.49 26.49	14.08	11.62	40.58 40.58	21.22 21.21	35.95	14.67 14.67	8.26 8.26	7.59 7.59	22.93 22.93	19.40 19.40	28.49 28.49	14.35 14.35	7.90	7.24 7.24	22.25 22.25	18.78 18.77	27.44
		Diluted Ero (iii nupees)	26.49	14.08	11.62	40.58	21.21	35.95	14.67	8.26	7.59	22.93	19.40	28.49	14.35	7.90	7.24	22.25	18.77	27.44

- 1 The above results were reviewed by the Audit Committee at its meeting held on 12 November, 2018 and approved at the meeting of the Board of Directors held on 13 November, 2018.
- 2 The results for the quarter and six month ended 30 September, 2018 presented were subjected to a "Limited Review" by statutory auditors of the Company who have issued an unmodified report on the said results. 3 During the quarter, the Company acquired 100 % stake of Zorg Laboratories Private Limited, presently known as Glenmark Life Sciences
- Limited, for a consideration of Rs. 0.3 million. As a result, Glenmark Life Sciences Limited has become a wholly owned subsidiary of the
- 4 On 25 September, 2018, Shareholders of the Company approved the transfer of Active Pharmaceutical Ingredients (API) business to its wholly owned subsidiary, Glenmark Life Sciences as a going concern by way of a slump sale. The Company is in the process of completing transfer as of 30 September 2018, and in accordance with the requirements of Ind AS 105, Non-current assets held for sale and discontinued operations, has disclosed the results of API business as discontinuing operations in the standalone financial results for all the periods presented. Further, the assets and liabilities pertaining to the API business as of 30 September 2018 have been disclosed separately in the standalone statement of financial position, in line with the aforementioned accounting standard.
- 5 During the quarter ended 30 September, 2018, the Company transferred its Orthopaedic and Pain management India business, valued at Rs. 6,350 million to Integrace Private Limited (Integrace) by way of a slump sale
- 6 Exceptional item: Exceptional items in the standalone (Ind AS) financial results for the quarter and half year ended 30 September 2018, $primarily\ comprises\ of\ net\ gain\ of\ Rs.\ 3,451.85\ million\ towards\ the\ sale\ of\ Orthopaedic\ and\ Pain\ management\ India\ business\ (Ortho\ India\ primarily\ comprises\ of\ primarily\ comp$ business), as described in note 5 above. Exceptional items in the consolidated financial results (Ind AS and IFRS) for the quarter and half year ended 30 September 2018 primarily comprises of the gain of Rs. 3,451.85 million towards the sale of Ortho India business and effect of de-prioritization of certain intangibles aggregating to Rs. 1,780.03 million.
- 7 The Financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing and Disclosure Requirements) Regulations, 2015 and SEBI circular dated 5 July, 2016. The Company has voluntarily presented the consolidated results in accordance with the recognition and measurement principles as per the IFRS in the format as per the Regulation 33(1)(c) of the SEBI (Listing and Disclosure Requirements) Regulations, 2015.
- 8 Effective 1 April, 2018, the Company adopted IND AS 115 or IFRS 15 "Revenue from Contracts with customers", as the case may be using the modified retrospective transition method. There was no material effect on the financial results on adoption of IND AS 115 or IFRS 15, as
- 9 The list of subsidiaries as of 30 September, 2018 is provided in Annexure A
- 10 The Company operates in one reportable business segment i.e., Pharmaceuticals. 11 As at 30 September, 2018, pursuant to Employee Stock Options Scheme 2016, 6,06,914 options were outstanding, which upon exercise
- are convertible into equivalent number of equity shares.
- 12 Diluted EPS has been computed considering the effect of conversion of ESOPs.
- 13 Post implementation of Goods and Service Tax ('GST') with effect from 1 July, 2017, revenue from operations is disclosed net of GST. Revenue from operations for the earlier period includes excise duty which is now subsumed in GST. Revenue from operations for year $ended \, 31 \, March, \, 2018 \, includes \, excise \, duty \, up to \, 30 \, June, \, 2017. \, Accordingly, \, revenue \, from \, operations \, for \, six \, month \, ended \, 30 \, September, \, and \, continuous \, con$ 2018 is not comparable with previous periods presented.
- 14 Previous period's figures have been re-grouped/re-classified wherever necessary.

Glenmark Pharmaceuticals Limited Annexure A

List of entities included in the consolidated financial results for the quarter and half year ended 30 September 2018

1) Glenmark Pharmaceuticals (Europe) R&D Ltd., U.K.2) Glenmark Pharmaceuticals Europe Ltd., U.K. 3) Glenmark Pharmaceuticals S.R.O.4) Glenmark Pharmaceuticals SK, S.R.O.5) Glenmark Pharmaceuticals S. A. 6) Glenmark Holding S.A. 7)Glenmark Pharmaceuticals S.R.L 8)Glenmark Pharmaceuticals SP z.o.o. 9) Glenmark Pharmaceuticals Inc. (formerly known as Glenmark Generics Inc.) 10) Glenmark Therapeutics Inc. 11) Glenmark Farmaceutica Ltda 12) Glenmark Generics S.A 13) Glenmark Pharmaceuticals Mexico, S.A. DE C.V. 14) Glenmark Pharmaceuticals Peru SAC 15) Glenmark Pharmaceuticals Colombia SAS, Colombia (Formerly known as Glenmark Pharmaceuticals Colombia Ltda., Colombia) 16) Glenmark Uruguay S.A. 17) Glenmark Pharmaceuticals Venezuela, C.A 18) Glenmark Dominicana SRL 19) Glenmark Pharmaceuticals Egypt S.A.E. 20) Glenmark Pharmaceuticals FZE 21) Glenmark Impex L.L.C 22) Glenmark Philippines Inc. 23) Glenmark Pharmaceuticals (Nigeria) Ltd 24) Glenmark Pharmaceuticals Malaysia Sdn Bhd 25) Glenmark Pharmaceuticals (Australia) Pty Ltd 26)Glenmark South Africa (pty) Ltd 27)Glenmark Pharmaceuticals South Africa (pty) Ltd 28)Glenmark Pharmaceuticals (Thailand) Co. Ltd 29) Glenmark Pharmaceuticals B.V. (Formerly known as Glenmark Generics B.V.) 30) Glenmark Arzneimittel Gmbh 31) Glenmark Pharmaceuticals Canada Inc. (formerly known as Glenmark Generics Canada Inc.) 32) Glenmark Pharmaceuticals Kenya Ltd 33) Glenmark Therapeutics AG 34) Viso Farmaceutica S.L., Spain 35) Glenmark Specialty SA 36) Glenmark Pharmaceuticals Distribution s.r.o. 37) Glenmark Pharmaceuticals Nordic AB 38) Glenmark Ukraine LLC 39)Glenmark-Pharmaceuticals Ecuador S.A. 40)Glenmark Pharmaceuticals Singapore Pte. Ltd. 41)Glenmark Biotherapeutics SA 42) Glenmark Life Sciences Limited (Formerly known as Zorg Laboratories Private Limited)

Balance Sheet (All amounts in million of Indian Rupees, unless otherwise stated)

CONSOLIDATED
Ind AS IFRS Ind AS Ind AS Ind AS IFRS As at 30.09.2018 Unaudited As at 31.03.2018 Audited As at 30.09.2018 As at 31.03.2018 Audited As at 31.03.2018 Audited Unaudited **ASSETS** Non current assets Property, plant and equipment 11,425.23 15,766.49 19,518.67 18,958.10 22,260.90 21,733.74 12,195.54 3,096.68 3,540.42 9,933.40 12,598.25 10,347.15 Capital work-in-progress Goodwill 547.35 521.04 547.35 521.04 1,224.73 Other Intangible Assets 1,101.28 12,620.19 10,816.38 14,929.87 13,296.47 Intangible Assets under development 715.51 656.33 1,494.84 1,285.32 1,494.84 1,285.32 **Financial Assets** 32,324.62 32,126.84 296.35 146.61 296.35 146.61 (i) Investments 55,786.92 33,028.48 (ii) Loans and advances 390.37 380.91 434.84 401.18 434.84 401.18 (iii) Other financial assets 13,804.24 12,201.76 7,449.24 6,606.15 13,202.60 12,828.22 Deferred tax assets (net) Other non-current assets 528.78 565.85 951.19 802.23 549.36 389.36 65,939.98 1,12,818.63 93,896.20 60,322.63 Total non- current assets 61,863.21 56,066.86 **Current assets** 7,284.09 11,111.80 20,576.67 20,305.85 20,576.67 20,305.85 Inventories **Financial Assets** (i) Investments 28,504.16 38,289.08 25,613.95 23,318.07 25,613.95 23,318.07 (ii) Trade receivables (iii) Cash and cash equivalents 12,333.56 3,903.71 1,760.47 13,157.88 12,333.56 13,157.88 (iv) Bank balance other than cash and cash equivalents 12.84 13.35 12.84 13.35 13.35 (v) Other financial assets 1,948.72 1,937.10 4,107.45 3,856.42 4,107.45 3,856.42 Current tax assets Other current assets 5,830.74 5.640.71 10,971.80 10,059.67 10,971.80 10,059.67 Total current assets 47,484.26 58,752.51 74,440.59 69,886.92 74,440.59 69,886.92 Assets to be transferred 12,907.99 1,52,648.71 1,36,303.80 1,25,953.78 1,40,380.57 1,30,209.55 Total assets 1,73,210.88 **EQUITY AND LIABILITIES** Equity Equity Share capital 282.17 282.17 282.17 282.17 282.17 282.17 1,15,079.66 1,03,632.24 54,671.16 51,352.60 58,747.93 Other Equity 55,608.37 Minority interest (3.70)(3.70)Liabilities Non-current liabilities **Financial Liabilities** 30,570.58 26,860.29 41,209.12 41,209.12 41,417.78 (i) Borrowings 41,417.78 (ii) Other financial liabilities 759.04 759.04 759.04 26.00 Deferred tax liabilities (net) Other non- current liabilities 31,329.62 26,886.29 41,973.00 41,443.78 41,973.00 41,443.78 Total non-current liabilities Current liabilities Financial Liabilities (i) Borrowings 3,064.12 2,950.44 3,064.12 2,950.44 3,064.12 2,950.44 (ii) Other financial liabilities 1,770.11 1,848.86 7,152.51 5,657.89 7,152.51 5,657.89 16,384.36 15,549.53 21,598.61 18,697.84 21,598.61 18,697.84 (iii) Trade payables Other current liabilities 419.05 567.19 1,014.13 1,248.12 1,014.13 1,248.12 **Provisions** 824.70 783.58 4,373.58 4,040.38 4,373.58 4,040.38 Current tax liabilities (Net) 2,066.14 148.41 2,178.57 284.26 2,178.57 284.26 Total current liabilities 24,528.48 21,848.01 39,381.52 32,878.93 39,381.52 32,878.93 **Total liabilities** 55,858.10 48,734.30 81,354.52 74,322.71 81,354.52 74,322.71 Liabilities to be transferred 1,990.95 1,25,953.78 1,40,380.57 1,73,210.88 1,52,648.71 1,36,303.80 1,30,209.55 Total equity and liabilities

For and on behalf of the Board of Directors Glenn Saldanha Chairman & Managing Director

(₹in Millions

Mumbai, November 13, 2018

प्रतिनिधी, मुंबई

वाहतुकीच्या दृष्टीने मोक्याचा शीव उड्डाणपूल डागडुजीसाठी डिसेंबरच्या पहिल्या आठवड्यापासून तीन महिन्यांसाठी बंद राहणार आहे. राज्य रस्ते विकास महामंडळाने

(एमएसआरडीसी) हा निर्णय घेतला असला तरी पर्यायी मार्गिकांचा आणि डागडुजीच्या एकूण नियोजनाचा अहवाल महामंडळाने अजूनही वाहतूक नियंत्रण विभागाला पाठवला नसल्याचे समोर आले आहे.

शहरातून पूर्व उपनगराच्या दिशेने

शीव उड्डाणपूल तीन महिने डागडुजीसाठी बंद होणार

जाण्यासाठी हा उड्डाणपूल महत्त्वपूर्ण खाबांशी धरून ठेवणारी १६० पुलाच्या ११ मीटर अंतरातील २२ दुवा आहे. २००० मध्ये बांधलेल्या या बेअरिंग नादुरुस्त झाल्याने त्या सांधेही बदलावे लागणार आहेत. मात्र पुलाची आता १८ वर्षांनी दुरुस्ती होत बदलाव्या लागणार आहेत. शिवाय या दरम्यान पर्यायी मार्गच नसल्याने

आहे. या कालावधीत पुलाला तब्बल ७५० मीटर लांबीच्या या प्रचंड वाहतूक कोंडी होणार आहे.

दरम्यान, ही दुरुस्ती नेमकी कशी होणार आहे, या संदर्भातील माहिती अजूनही महामंडळाने वाहतूक विभागाला दिलेली नाही. पुलाच्या

दुरुस्तीबाबत निर्णय झाल्यावरच त्यासंबंधीची माहिती वाहतूक विभागाला देणे आवश्यक होते. मात्र तसे न झाल्याने वाहतुकीचे नियोजन कसे करावे, याबाबत कोणताही निर्णय वाहतुक विभागाला घेता आलेला नाही.

डागडुजीच्या नियोजनाबाबतीचा विस्तृत अहवाल तयार करण्याचे आदेश कंत्राटदाराला दिले असून येत्या काही दिवसांमध्ये अहवाल वाहतूक विभागाला पाठविला जाईल, असे त्या अधिकाऱ्याने सांगितले.

glenmark

PHARMACEUTICALS LTD.

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai 400 026.

Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Andheri (East), Mumbai 400 099.

Tel: 91 22 4018 9999 Fax: 91 22 4018 9986 Email: complianceofficer@glenmarkpharma.com Website: www.glenmarkpharma.com

CIN: L24299MH1977PLC019982

Statement of unaudited financial results for the quarter and half year ended 30 September, 2018

	Statement of unaudited financial results for t						ne quarter and hair year end					red 30 September, 2018 (7 in Millions)							
	Standalone (Ind AS)					Consolidated (Ind AS)					Consolidated (IFRS)								
	Particulars (Defendance to Lour)	Quarter Ended 30-09-2018	Quarter Ended 30-06-2018	Quarter Ended 30-09-2017	Half Year Ended 30-09-2018	Half Year Ended 30-09-2017	Year Ended 31-03-2018	Quarter Ended 30-09-2018	Quarter Ended 30-06-2018	Quarter Ended 30-09-2017	Half Year Ended 30-09-2018	Half Year Ended 30-09-2017	Year Ended 31-03-2018	Quarter Ended 30-09-2018	Quarter Ended 30-06-2018	Quarter Ended 30-09-2017	Half Year Ended 30-09-2018	Half Year Ended 30-09-2017	Year Ended 31-03-2018
	(Refer notes below)	(Unudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	40.000.40	40.000.00	40.044.00	00.004.00	00 005 00	E0 404 45	05 000 55	04 000 00	00.004.40	40.000.00	45 500 0	00 700 00	05 000 55	04 000 00	00.004.40	40.000.00	4E E00 0 :	00 700 00
	(a) Net sales (b) Other operating income	16,398.12 399.03	13,606.68 451.69	13,911.26 360.76	30,004.80 850.72	26,995.29 684.09	52,434.15 3,007.93	25,398.57 414.75	21,293.66 362.51	22,234.40 331.50	46,692.23 777.26	45,528.34 667.58	89,722.32 1,308.38	25,398.57 414.75	21,293.66 362.51	22,234.40 331.50	46,692.23 777.26	45,528.34 667.58	89,722.32 1,308.38
	Total Revenue from operations	16,797.15	14,058.37	14,272.02	30,855.52	27,679.38	55,442.08	25,813.32	21,656.17	22,565.90	47,469.49	46,195.92	91,030.70	25,813.32		22,565.90	47,469.49	46,195.92	
П	Other income	2,263.02	1,655.64	563.04	3,918.66	988.66	1,799.92	1,398.79	1,382.16	297.26	2,780.95	450.13	914.00	1,398.62	1,382.16	297.26	2,780.78	450.13	914.00
III	Total income (I + II)	19,060.17	15,714.01	14,835.06	34,774.18		57,242.00	27,212.11	23,038.33	22,863.16		46,646.05	91,944.70		23,038.33	22,863.16	50,250.27	46,646.05	
IV	Expenses																		
	a) Cost of materials consumed	3,859.17	4,084.98	3,776.36	7,944.15	7,564.84	16,480.25	6,032.60	4,951.83	5,443.85	10,984.43	10,300.52	21,501.10	6,032.60	4,951.83	5,443.85	10,984.43	0.000	21,501.10
	 b) Purchase of stock-in-trade c) Changes in inventories of finished goods, 	881.14	746.72	664.07	1,627.86	1,357.13	2,881.77	2,678.13	2,452.52	1,342.18	5,130.65	3,951.34	7,547.45	2,678.13	2,452.52	1,342.18	5,130.65	3,951.34	7,547.45
Ш	work-in-progress and stock-in-trade	1,134.01	440.08	877.04	1,574.09	1,357.55	1,397.14	97.36	183.62	726.44	280.98	475.07	1,337.12	97.36	183.62	726.44	280.98	475.07	1,337.12
Ш	d) Employee benefits expense	3,123.98	2,012.70	2,867.65	5,136.68	4,687.79	8,956.71	6,058.95	4,525.09	5,572.30	10,584.04	9,416.26	18,718.41	6,058.95	4,525.09	5,572.30	10,584.04	9,416.26	18,718.41
Ш	e) Finance costs	608.53	551.71	474.41	1,160.24	931.78	1,908.98	851.27	790.12	698.44	1,641.39	1,407.05	2,855.67	851.27	790.12	698.44	1,641.39	1,407.05	2,855.67
Ш	f) Depreciation and Amortisation expense	269.23	273.05	235.12	542.28	481.91	959.27	824.50	793.84	752.28	1,618.34	1,529.60	3,018.76	933.67	944.78	874.05	1,878.45	1,751.26	3,540.67
Ш	g) Other expenses	3,880.74	3,598.25	2,882.90	7,478.99	6,610.89	14,716.17	6,545.22	6,074.28	5,597.17	12,619.50	12,394.28	25,772.89	6,545.22	6,074.28	5,597.55	12,619.50	12,395.37	25,776.33
H .,,	Total expenses (IV)	13,756.80	11,707.49	11,777.55	25,464.29	22,991.89	47,300.29	23,088.03	19,771.30	20,132.66	42,859.33	39,474.12	80,751.40	23,197.20	19,922.24	20,254.81	43,119.44		81,276.75
V	Profit/(loss) before exceptional items and tax(III - IV) Exceptional items	5,303.37 (3,451.85)	4,006.52	3,057.51	9,309.89 (3,451.85)	5,676.15	9,941.71	4,124.08 (1,671.82)	3,267.03	2,730.50	7,391.11 (1,671.82)	7,171.93	11,193.30	4,014.74 (1,671.82)	3,116.09	2,608.35	7,130.83 (1,671.82)	6,949.18	10,667.95
VII		8,755.22	4,006.52	3,057.51	12,761.74	5,676.15	9,941.71	5,795.90	3,267.03	2,730.50	9,062.93	7,171.93	11,193.30	5,686.56	3,116.09	2,608.35	8,802.65	6,949.18	10,667.95
VIII		0,100.22	1,000.02	0,007.01	12,101.11	0,010.10	0,01111	0,100.00	0,207.00	2,700.00	0,002.00	,,,,,,,,	71,100.00	0,000.00	0,1,10,00	2,000.00	0,002.00	0,010110	10,007.00
Ш	Current tax	1,915.64	761.55	581.67	2,677.19	1,086.25	2,018.21	2,145.00	1,116.28	976.19	3,261.28	1,766.32	3,256.90	2,145.00	1,116.28	976.19	3,261.28	1,766.32	3,244.11
	Deferred tax	(186.17)	(105.20)	(329.21)	(291.37)	(540.25)	(735.11)	(489.10)	(179.15)	(386.89)	(668.25)	(69.40)	(102.30)	(507.71)	(227.98)	(410.95)	(735.69)	(115.02)	(318.99)
IX																			
Ⅱ 、	from continuing operations (VII - VIII)	7,025.75	3,350.17	2,805.05	10,375.92	5,130.15	8,658.61	4,140.00	2,329.90	2,141.20	6,469.90	5,475.01	8,038.70	4,049.27	2,227.79	2,043.11	6,277.06	5,297.88	7,742.83
^	Profit/(loss) for the period from continuing operations (V - VI)	683.02	947.07	716.74	1,630.09	1,296.62	2,246.54				٠.								
l xı		000.02	347.07	710.74	1,000.03	1,200.02	2,240.04				100				1/2	A-9	100	10.0	
***	Current tax	222.51	308.53	219.68	531.04	397.41	688.56			-				-	-				-
5 1932	Deferred tax	10.67	14.80	23.32	25.47	42.19	73.12	_	2	-	-	0	-	-	_	2	-	-	-
XII		50,2520	02351	552222	79222	1000000	1975325555												
,,,,,	discontinuing operations (X - XI)	449.84	623.74	473.74	1,073.58	857.02	1,484.86	1		15	0-	14	-	-			(*)	-	-
XIII	Profit/(loss) for the period for continuing and discontinuing operations (IX + XII)	7,475.59	3,973.91	3,278.79	11,449.50	5,987.17	10,143.47	4,140.00	2,329.90	2,141.20	6,469.90	5,475.01	8,038.70	4,049.27	2,227.79	2,043.11	6,277.06	5,297.88	7,742.83
$ _{x_{IV}}$	Other comprehensive income	1,410.00	0,570.51	5,276.75	11,443.50	3,307.17	10,140.47	4,140.00	2,020.00	2,141.20	0,405.50	3,473.01	0,000.70	4,043.27	2,221.15	2,040.11	0,277.00	5,257.00	7,742.00
1 200	A (i) Items that will not be reclassified to profit or loss	(48.45)	25.10	(26.09)	(23.35)	(34.69)	(10.20)	3.74	28.10	50.33	31.84	34.87	41.96	3.74	28.10	50.33	31.84	34.87	41.96
Ш	(ii) Income tax relating to items that will not be	100000000000000000000000000000000000000	2,0216,0503	107,07 697 01000	10000000	3183 6883 58	15.65360.50		100030003	(10 (p) (0 12) (c) (c) (c) (c) (c) (c) (c) (c) (c) (c)	55%5506	27/32/02/216	260470353	199303	100000000000000000000000000000000000000		901.28121.033		85.8000.000
Ш	reclassified to profit or loss	16.93	(8.77)	9.02	8.16	12.00	3.53	10.15	(9.16)	(1.02)	0.99	2.96	(3.25)	10.15	(9.16)	(1.02)	0.99	2.96	(3.25)
Ш	B (i) Items that will be reclassified to profit or loss	10	-			15	15	(600.23)	(2,725.02)	(14.41)	(3,325.25)	(368.92)	(778.78)	(557.92)	(2,753.50)	55.73	(3,311.42)	(294.46)	(696.17)
Ш	(ii) Income tax relating to items that will be reclassified to profit or loss					10	12	127.67			127.67	8	100	127.67	160	100	127.67	199	
l xv	Total comprehensive income	7,444.07	3,990.24	3.261.72	11,434.31	5,964.48	10,136.80	3,681.33	(376.18)	2,176.10	3,305.15	5,143.92	7,298.63	3,632.91	(506.77)	2,148.15	3,126.14	5,041.25	7,085.37
XVI		1,	0,000.21	,,	,	0,00	10,100.00	0,0000	(0.00)	_,,,,,,,,,	0,000	0,1.0.02	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	0,002.01	(000)	_,,	0,	0,01120	1,,,,,,,,,,
Ш	- Non-controlling interests	10					-	(0.04)	(0.04)	(0.32)	(0.08)	(0.19)	0.92	(0.04)	(0.04)	(0.32)	(0.08)	(0.19)	0.92
H	- Owners of the Company	7,444.07	3,990.24	3,261.72	11,434.31	5,964.48	10,136.80	3,681.37	(376.14)	2,176.42	3,305.23	5,144.11	7,297.71	3,632.95	(506.73)	2,148.47	3,126.22	5,041.44	7,084.45
XVI				-		-	1,03,632.24	-				-	51,352.60				-		55,608.37
XVI	III Earning per share (EPS) (for continuing operations) (of Re 1/- each) (not annualised)																		
Ш	Basic EPS (in Rupees)	24.90	11.87	9.94	36.78	18.18	30.69	14.67	8.26	7.59	22.93	19.40	28.49	14.35	7.90	7.24	22.25	18.78	27.44
Ш	Diluted EPS (in Rupees)	24.90	11.87	9.94	36.78	18.17	30.69	14.67	8.26	7.59	22.93	19.40	28.49		7.90	7.24	22.25	18.77	27.44
XVI	II Earning per share (EPS) (for discontinuing operations)	C. C				11.50									0.00	2 1 TO 1		900.000.00	
	(of Re 1/- each) (not annualised)	1003113504	127.732	854.00	30000	1530750	202202												
	Basic EPS (in Rupees)	1.59	2.21	1.68	3.80	3.04	5.26	-	~	18	-	14	1-	-	199	18	84	-	-
VA.	Diluted EPS (in Rupees)	1.59	2.21	1.68	3.80	3.04	5.26		-		0.5					100			
XVII	II Earning per share (EPS) (for continuing and discontinuing operations)																		
	(of Re 1/- each) (not annualised)															ya.w.			
	Basic EPS (in Rupees)	26.49	14.08	11.62	40.58	21.22	35.95	14.67	8.26	7.59	22.93	19.40	28.49	14.35	7.90	7.24	22.25	18.78	27.44
	Diluted EPS (in Rupees)	26.49	14.08	550000000000000000000000000000000000000	72,300,000,000,000	21.21	35.95	14.67	8.26	7.59	22.93	19.40	2000			7.24	22.25		100000000000000000000000000000000000000

Total liabilities

Liabilities to be transferred

Total equity and liabilities

Notes:

- 1 The above results were reviewed by the Audit Committee at its meeting held on 12 November, 2018 and approved at the meeting of the Board of Directors held on 13 November, 2018.
- 2 The results for the guarter and six month ended 30 September, 2018 presented were subjected to a "Limited Review" by statutory auditors of the Company who have issued an unmodified report on the said results.
- 3 During the quarter, the Company acquired 100 % stake of Zorg Laboratories Private Limited, presently known as Glenmark Life Sciences Limited, for a consideration of Rs. 0.3 million. As a result, Glenmark Life Sciences Limited has become a wholly owned subsidiary of the
- 4 On 25 September, 2018, Shareholders of the Company approved the transfer of Active Pharmaceutical Ingredients (API) business to its wholly owned subsidiary, Glenmark Life Sciences as a going concern by way of a slump sale. The Company is in the process of completing transfer as of 30 September 2018, and in accordance with the requirements of Ind AS 105, Non-current assets held for sale and discontinued operations, has disclosed the results of API business as discontinuing operations in the standalone financial results for all the periods presented. Further, the assets and liabilities pertaining to the API business as of 30 September 2018 have been disclosed separately in the standalone statement of financial position, in line with the aforementioned accounting standard.
- 5 During the quarter ended 30 September, 2018, the Company transferred its Orthopaedic and Pain management India business, valued at Rs. 6,350 million to Integrace Private Limited (Integrace) by way of a slump sale.
- 6 Exceptional item: Exceptional items in the standalone (Ind AS) financial results for the guarter and half year ended 30 September 2018, primarily comprises of net gain of Rs. 3,451.85 million towards the sale of Orthopaedic and Pain management India business (Ortho India business), as described in note 5 above. Exceptional items in the consolidated financial results (Ind AS and IFRS) for the guarter and half year ended 30 September 2018 primarily comprises of the gain of Rs. 3,451.85 million towards the sale of Ortho India business and effect of de-prioritization of certain intangibles aggregating to Rs. 1,780.03 million.
- 7 The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing and Disclosure Requirements) Regulations, 2015 and SEBI circular dated 5 July, 2016. The Company has voluntarily presented the consolidated results in accordance with the recognition and measurement principles as per the IFRS in the format as per the Regulation 33(1)(c) of the SEBI (Listing and Disclosure Requirements) Regulations, 2015.
- 8 Effective 1 April, 2018, the Company adopted IND AS 115 or IFRS 15" Revenue from Contracts with customers", as the case may be using the modified retrospective transition method. There was no material effect on the financial results on adoption of IND AS 115 or IFRS 15, as
- 9 The list of subsidiaries as of 30 September, 2018 is provided in Annexure A.
- 10The Company operates in one reportable business segment i.e., Pharmaceuticals. 11 As at 30 September, 2018, pursuant to Employee Stock Options Scheme 2016, 6,06,914 options were outstanding, which upon exercise
- are convertible into equivalent number of equity shares. 12 Diluted EPS has been computed considering the effect of conversion of ESOPs.
- 13 Post implementation of Goods and Service Tax ('GST') with effect from 1 July, 2017, revenue from operations is disclosed net of GST. Revenue from operations for the earlier period includes excise duty which is now subsumed in GST. Revenue from operations for year ended 31 March, 2018 includes excise duty upto 30 June, 2017. Accordingly, revenue from operations for six month ended 30 September, 2018 is not comparable with previous periods presented.
- 14 Previous period's figures have been re-grouped/re-classified wherever necessary.

Glenmark Pharmaceuticals Limited Annexure A

List of entities included in the consolidated financial results for the quarter and half year ended 30 September 2018

Name of Entities: Glenmark Pharmaceuticals (Europe) R&D Ltd., U.K.2)Glenmark Pharmaceuticals Europe Ltd., U.K. 3)Glenmark Pharmaceuticals S.R.O.4) Glenmark Pharmaceuticals SK, S.R.O.5) Glenmark Pharmaceuticals S. A. 6) Glenmark Holding S.A. 7) Glenmark Pharmaceuticals S.R.L 8) Glenmark Pharmaceuticals SP z.o.o. 9) Glenmark Pharmaceuticals Inc. (formerly known as Glenmark Generics Inc.) 10)Glenmark Therapeutics Inc. 11) Glenmark Farmaceutica Ltda 12)Glenmark Generics S.A 13) Glenmark Pharmaceuticals Mexico, S.A. DE C.V. 14) Glenmark Pharmaceuticals Peru SAC 15) Glenmark Pharmaceuticals Colombia SAS, Colombia (Formerly known as Glenmark Pharmaceuticals Colombia Ltda., Colombia) 16) Glenmark Uruguay S.A. 17) Glenmark Pharmaceuticals Venezuela, C.A 18) Glenmark Dominicana SRL 19) Glenmark Pharmaceuticals Egypt S.A.E. 20) Glenmark Pharmaceuticals FZE 21) Glenmark Impex L.L.C 22) Glenmark Philippines Inc. 23) Glenmark Pharmaceuticals (Nigeria) Ltd 24) Glenmark Pharmaceuticals Malaysia Sdn Bhd 25) Glenmark Pharmaceuticals (Australia) Pty Ltd 26)Glenmark South Africa (pty) Ltd 27)Glenmark Pharmaceuticals South Africa (pty) Ltd 28)Glenmark Pharmaceuticals (Thailand) Co. Ltd 29)Glenmark Pharmaceuticals B.V.(Formerly known as Glenmark Generics B.V.) 30) Glenmark Arzneimittel Gmbh 31) Glenmark Pharmaceuticals Canada Inc. (formerly known as Glenmark Generics Canada Inc.) 32) Glenmark Pharmaceuticals Kenya Ltd 33) Glenmark Therapeutics AG 34) Viso Farmaceutica S.L., Spain 35) Glenmark Specialty SA 36) Glenmark Pharmaceuticals Distribution s.r.o. 37) Glenmark Pharmaceuticals Nordic AB 38) Glenmark Ukraine LLC 39)Glenmark-Pharmaceuticals Ecuador S.A. 40)Glenmark Pharmaceuticals Singapore Pte. Ltd. 41)Glenmark Biotherapeutics SA 42) Glenmark Life Sciences Limited (Formerly known as Zorg Laboratories Private Limited)

14.67 8.26 7.59	22.93 19.40	28.49	14.35 7.90	7.24	22.25	18.77 27.44						
Balance Sheet (All amounts in million of Indian Rupees, unless otherwise stated) (₹ in Millions												
	STAN	IDALONE		CONS	OLIDATED							
	Ind AS	Ind AS	Ind AS	Ind AS	IFRS	IFRS						
	As at	As at	As at	As at	As at	As at						
	30.09.2018 Unaudited	31.03.2018 Audited	30.09.2018 Unaudited	31.03.2018 Audited	30.09.2018 Unaudited	31.03.2018 Audited						
ASSETS		Si .										
Non current assets												
Property, plant and equipment	11,425.23	15,766.49	19,518.67	18,958.10	22,260.90	21,733.74						
Capital work-in-progress	3,096.68	3,540.42	12,195.54	9,933.40	12,598.25	10,347.15						
Goodwill		-	547.35	521.04	547.35	521.04						
Other Intangible Assets	1,101.28	1,224.73	12,620.19	10,816.38	14,929.87	13,296.47						
Intangible Assets under developmen	nt 715.51	656.33	1,494.84	1,285.32	1,494.84	1,285.32						
Financial Assets												
(i) Investments	32,324.62	32,126.84	296.35	146.61	296.35	146.61						
(ii) Loans and advances	55,786.92	33,028.48	-		-	-						
(iii) Other financial assets	390.37	380.91	434.84	401.18	434.84	401.18						
Deferred tax assets (net)	7,449.24	6,606.15	13,804.24	13,202.60	12,828.22	12,201.76						
Other non-current assets	528.78	565.85	951.19	802.23	549.36	389.36						
Total non- current assets	1,12,818.63	93,896.20	61,863.21	56,066.86	65,939.98	60,322.63						
Current assets	0.000 2000	30 100170301	1000 00000	10000000 10	55.05% 56950	10/0/50/57 129						
Inventories	7,284.09	11,111.80	20,576.67	20,305.85	20,576.67	20,305.85						
Financial Assets		500000000000000000000000000000000000000	SSSCRI GEARGESTO			0.0000000000000000000000000000000000000						
(i) Investments		(-)		1.0		*						
(ii) Trade receivables	28,504.16	38,289.08	25,613.95	23,318.07	25,613.95	23,318.07						
(iii) Cash and cash equivalents	3,903.71	1,760.47	13,157.88	12,333.56	13,157.88	12,333.56						
(iv) Bank balance other than cash	100											
and cash equivalents	12.84	13.35	12.84	13.35	12.84	13.35						
(v) Other financial assets	1,948.72	1,937.10	4,107.45	3,856.42	4,107.45	3,856.42						
Current tax assets	-	-	-	-	-	-						
Other current assets	5,830.74	5,640.71	10,971.80	10,059.67	10,971.80	10,059.67						
Total current assets	47,484.26	58,752.51	74,440.59	69,886.92	74,440.59	69,886.92						
Assets to be transferred	12,907.99											
Total assets	1,73,210.88	1,52,648.71	1,36,303.80	1,25,953.78	1,40,380.57	1,30,209.55						
EQUITY AND LIABILITIES												
Equity	200.47	000.47	000.47	000.47	000.47	000.47						
Equity Share capital	282.17	282.17	282.17	282.17	282.17	282.17						
Other Equity	1,15,079.66	1,03,632.24	54,671.16	51,352.60	58,747.93	55,608.37						
Minority interest Liabilities	17		(4.05)	(3.70)	(4.05)	(3.70)						
Non-current liabilities												
Financial Liabilities												
(i) Borrowings	30,570.58	26,860.29	41,209.12	41,417.78	41,209.12	41,417.78						
(ii) Other financial liabilities	759.04	26.00	759.04	26.00	759.04	26.00						
Deferred tax liabilities (net)	700.04	20.00	700.04	20.00	700.04	20.00						
Other non- current liabilities		120	4.84	1/2	4.84	27						
Total non-current liabilities	31,329.62	26,886.29	41,973.00	41,443.78	41,973.00	41,443.78						
Current liabilities	0.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	20,000.20	,	,	,	1,,						
Financial Liabilities												
(i) Borrowings	3,064.12	2,950.44	3,064.12	2,950.44	3,064.12	2,950.44						
(ii) Other financial liabilities	1,770.11	1,848.86	7,152.51	5,657.89	7,152.51	5,657.89						
(iii) Trade payables	16,384.36	15,549.53	21,598.61	18,697.84	21,598.61	18,697.84						
Other current liabilities	419.05	567.19	1,014.13	1,248.12	1,014.13	1,248.12						
Provisions	824.70	783.58	4,373.58	4,040.38	4,373.58	4,040.38						
Current tax liabilities (Net)	2,066.14	148.41	2,178.57	284.26	2,178.57	284.26						
Total current liabilities	24,528.48	21,848.01	39,381.52	32,878.93	39,381.52	32,878.93						
Total lightlities	EE 050 10	40 724 20	04 254 50	74 200 74	04 254 50	74 200 74						

55,858.10

1,73,210.88

1,990.95

48,734.30

1,52,648.71

81,354.52

1,36,303.80

74,322.71

1,25,953.78

For and on behalf of the Board of Directors Glenn Saldanha Chairman & Managing Director

81,354.52

1,40,380.57

74,322.71

1.30,209.55

Mumbai, November 13, 2018